Novo Nordisk A/S (NYSE:NVO) Holdings Boosted by PFG Investments LLC

PFG Investments LLC boosted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 120.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 31,208 shares of the company's stock after purchasing an additional 17,065 shares during the period. PFG Investments LLC's holdings in Novo Nordisk A/S were worth $4,007,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Outlook Wealth Advisors LLC grew its position in Novo Nordisk A/S by 17.9% during the 1st quarter. Outlook Wealth Advisors LLC now owns 3,400 shares of the company's stock worth $437,000 after purchasing an additional 517 shares in the last quarter. Raymond James & Associates grew its position in Novo Nordisk A/S by 12.1% during the 1st quarter. Raymond James & Associates now owns 3,143,731 shares of the company's stock worth $403,655,000 after purchasing an additional 340,549 shares in the last quarter. Aurora Private Wealth Inc. purchased a new position in Novo Nordisk A/S during the 1st quarter worth approximately $234,000. Shikiar Asset Management Inc. grew its position in Novo Nordisk A/S by 2.2% during the 1st quarter. Shikiar Asset Management Inc. now owns 129,840 shares of the company's stock worth $16,671,000 after purchasing an additional 2,800 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC grew its position in Novo Nordisk A/S by 19.5% during the 1st quarter. Ashton Thomas Private Wealth LLC now owns 14,536 shares of the company's stock worth $1,866,000 after purchasing an additional 2,374 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

NVO has been the topic of several research analyst reports. UBS Group initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a "neutral" rating on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an "overweight" rating and a $120.00 price target on the stock. Finally, BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They set an "outperform" rating and a $163.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $133.60.

Novo Nordisk A/S Stock Up 0.8 %

Shares of NVO stock traded up $1.06 on Friday, hitting $126.85. The company's stock had a trading volume of 3,312,457 shares, compared to its average volume of 3,307,405. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The firm's fifty day moving average price is $126.86 and its 200-day moving average price is $112.11. The stock has a market capitalization of $569.24 billion, a price-to-earnings ratio of 46.89, a P/E/G ratio of 2.10 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The business had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Research analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were given a dividend of $0.664 per share. This is a positive change from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. This represents a yield of 0.9%. Novo Nordisk A/S's payout ratio is currently 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.